Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DS-8201a DDI study with Ritonavir or Itraconazole in HER2+ solid tumors
NCT03383692Phase 1Completed
- Sponsor
- Daiichi Sankyo Co., Ltd.
- Start
- Jan 2018
- Primary completion
- Sep 2018
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 3
01
Overview
Phase 1, open-label trial of trastuzumab deruxtecan in HER2-positive solid tumor (2 cohorts), sponsored by Daiichi Sankyo Co., Ltd. Primary endpoints: Maximum Observed Serum Concentration (Cmax) for DS-8201a at Cycle 3, Maximum Observed Serum Concentration (Cmax) for MAAA-1181a at Cycle 3 and 2 more. Started Jan 2018; status: completed.
02
Drugs
trastuzumab deruxtecan
03
Conditions
HER2-positive solid tumor
Beyond the preview
Go deeper on NCT03383692.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03383692.